Akero Therapeutics Inc

Change company Symbol lookup

Select an option...

AKRO Akero Therapeutics Inc

LPRO Open Lending Corp

SLGL Sol Gel Technologies Ltd

UAVS Ageagle Aerial Systems Inc

IWSY ImageWare Systems Inc

AMPX Amprius Technologies Inc

TNC Tennant Co

CVX Chevron Corp

ACGLO Arch Capital Group Ltd

AAPL Apple Inc

Go

Akero Therapeutics, Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.